Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches

References

• 1 Parkinson J. An Essay on the Shaking Palsy. Whittingham and Rowland for Sherwood, Neely, and Jones, London, UK (1817).
  Google Scholar
• 2 Stern G, Lees A. Parkinson's Disease: The Facts. Oxford University Press, Oxford, UK (1990).
  Google Scholar
• 3 Manyam BV. Practical guidelines for management of Parkinson disease. J. Am. Board Fam. Pract. 10(6), 412–424 (1997).
  Medline CASGoogle Scholar
• 4 Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol. Clin. 14(2), 317–335 (1996).
  Medline CASGoogle Scholar
• 5 Poewe W, Seppi K, Tanner CM et al. Parkinson disease. Nat. Rev. Dis. Primers 3, 17013 (2017).
  MedlineGoogle Scholar
• 6 Marsden CD. The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 32(5), 514–539 (1982).
  Medline CASGoogle Scholar
• 7 Shahed J, Jankovic J. Motor symptoms in Parkinson's disease. Handb. Clin. Neurol. 83, 329–342 (2007).
  MedlineGoogle Scholar
• 8 Robbins JA, Logemann J, Krishner H. Swallowing and speech production in Parkinson's disease. Ann. Neurol. 19, 283–287 (1986).
  Medline CASGoogle Scholar
• 9 Sawashima M, Hirose H. Laryngeal gestures in speech production. In: MacNeilage PF (Ed.). The Production of Speech. Springer, NY, USA, 11–38 (1983).
  Google Scholar
• 10 MacNeilage PF. The Production of Speech. Springer Science & Business Media, NY, USA (2012).
  Google Scholar
• 11 Redford MA. The Handbook of Speech Production. John Wiley & Sons, NJ, USA (2015).
  Google Scholar
• 12 Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 29(13), 1583–1590 (2014).
  MedlineGoogle Scholar
• 13 Zamuner TS, Yeung HH, Ducos M. The many facets of speech production and its complex effects on phonological processing. Brit. J. Psychol. 108(1), 37–39 (2017).
  MedlineGoogle Scholar
• 14 Rusz J, Cmejla R, Ruzickova H, Ruzicka E. Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson's disease. J. Acoust. Soc. Am. 129(1), 350–367 (2011).
  Medline CASGoogle Scholar
• 15 Rueda A, Krishnan S. Feature analysis of dysphonia speech for monitoring Parkinson's disease. Presented at: Engineering in Medicine and Biology Society (EMBC), 2017 39th Annual International Conference of the IEEE. Jeju City, Korea, 11 July 2017.
  Google Scholar
• 16 De Keyser K, Santens P, Bockstael A et al. The relationship between speech production and speech perception deficits in parkinson's disease. J. Speech Lang. Hear. Res. 59(5), 915–931 (2016).
  MedlineGoogle Scholar
• 17 Millian-Morell L, Lopez-Alburquerque T, Rodriguez-Rodriguez A et al. Relations between sensorimotor integration and speech disorders in Parkinson's disease. Curr. Alzheimer Res. 15(2), 149–156 (2018).
  Medline CASGoogle Scholar
• 18 Chen Y-W, Watson PJ. Speech production and sensory impairment in mild Parkinson's disease. J. Acoust. Soc. Am. 141(5), 3030–3041 (2017).
  MedlineGoogle Scholar
• 19 Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr. Logop. 46(1), 9–17 (1994).
  Medline CASGoogle Scholar
• 20 Breitenstein C, Van Lancker D, Daum I, Waters CH. Impaired perception of vocal emotions in Parkinson's disease: influence of speech time processing and executive functioning. Brain Cogn. 45(2), 277–314 (2001).
  Medline CASGoogle Scholar
• 21 Rusz J, Čmejla R, Růžičková H et al. Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy. J. Neural Transm. 120(2), 319–329 (2013).
  Medline CASGoogle Scholar
• 22 Trail M, Fox C, Ramig LO, Sapir S, Howard J, Lai EC. Speech treatment for Parkinson's disease. NeuroRehabilitation 20(3), 205–221 (2005).
  MedlineGoogle Scholar
• 23 Nerurkar AC, Sheth M. Facial, oromotor and speech disturbances in individuals with Parkinson's disease. Int. J. Ther. Rehabil. Res. 6(2), 217 (2017).
  Google Scholar
• 24 Schulz GM, Grant MK. Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's disease: a review of the literature. J. Commun. Disord. 33(1), 59–88 (2000).
  Medline CASGoogle Scholar
• 25 Skodda S, Visser W, Schlegel U. Gender-related patterns of dysprosody in Parkinson disease and correlation between speech variables and motor symptoms. J. Voice 25(1), 76–82 (2011).
  MedlineGoogle Scholar
• 26 Tsuboi T, Watanabe H, Tanaka Y et al. Early detection of speech and voice disorders in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation: a 1-year follow-up study. J. Neural Transm. 124(12), 1547–1556 (2017).
  MedlineGoogle Scholar
• 27 Skodda S, Rinsche H, Schlegel U. Progression of dysprosody in Parkinson's disease over time–a longitudinal study. Mov. Disord. 24(5), 716–722 (2009).
  MedlineGoogle Scholar
• 28 Lam J, Tjaden K. Clear speech variants: an acoustic study in Parkinson's disease. J. Speech Lang. Hear. Res. 59(4), 631–646 (2016).
  MedlineGoogle Scholar
• 29 Canter GJ. Speech characteristics of patients with Parkinson's disease: I intensity, pitch and duration. J. Speech Hear. Disord. 28, 221–229 (1963).
  Medline CASGoogle Scholar
• 30 Canter GJ. Speech characteristics of patients with Parkinson's disease. III. Articulation, diadochokinesis and over-all speech adequacy. J. Speech Hear. Disord. 30, 217–224 (1965).
  Medline CASGoogle Scholar
• 31 Canter GJ. Speech characteristics of patients with Parkinson's disease. II. Physiological support for speech. J. Speech Hear. Disord. 30, 44–49 (1965).
  Medline CASGoogle Scholar
• 32 Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J. Speech Lang. Hear. Res. 12(2), 246–269 (1969).
  CASGoogle Scholar
• 33 Darley FL, Aronson AE, Brown JR. Clusters of deviant speech dimensions in the dysarthrias. J. Speech Hear. Res. 12(3), 462–496 (1969).
  Medline CASGoogle Scholar
• 34 Lowit A. Quantification of rhythm problems in disordered speech: a re-evaluation. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369(1658), 20130404 (2014).
  MedlineGoogle Scholar
• 35 Kim Y, Kent RD, Weismer G. An acoustic study of the relationships among neurologic disease, dysarthria type and severity of dysarthria. J. Speech Lang. Hear. Res. 54(2), 417–429 (2011).
  MedlineGoogle Scholar
• 36 Tykalova T, Rusz J, Klempir J, Cmejla R, Ruzicka E. Distinct patterns of imprecise consonant articulation among Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Brain Lang. 165, 1–9 (2017).
  MedlineGoogle Scholar
• 37 Novotný M, Rusz J, Čmejla R, Růžičková H, Klempíř J, Růžička E. Hypernasality associated with basal ganglia dysfunction: evidence from Parkinson's disease and Huntington's disease. PeerJ. 4, e2530 (2016).
  MedlineGoogle Scholar
• 38 Miller N, Nath U, Noble E, Burn D. Utility and accuracy of perceptual voice and speech distinctions in the diagnosis of Parkinson's disease, PSP and MSA-P. Neurodegener. Dis. Manag. 7(3), 191–203 (2017).
  Google Scholar
• 39 Fox CM, Ramig LO. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am. J. Speech Lang. Pathol. 6(2), 85–94 (1997).
  Google Scholar
• 40 Abur D, Lupiani AA, Hickox AE, Shinn-Cunningham B, Stepp CE. Loudness perception of pure tones in Parkinson's disease. J. Acoust. Soc. Am. 141(5), 3900–3900 (2017).
  Google Scholar
• 41 Rusz J, Hlavnička J, Čmejla R, Růžička E. Automatic evaluation of speech rhythm instability and acceleration in dysarthrias associated with basal ganglia dysfunction. Front. Bioeng. Biotechnol. 3, 104 (2015).
  MedlineGoogle Scholar
• 42 Tykalova T, Rusz J, Cmejla R, Ruzickova H, Ruzicka E. Acoustic investigation of stress patterns in Parkinson's disease. J. Voice 28(1), 129. e121–129. e128 (2014).
  Google Scholar
• 43 Solomon NP, Hixon TJ. Speech breathing in Parkinson's disease. J. Speech Lang. Hear. Res. 36(2), 294–310 (1993).
  CASGoogle Scholar
• 44 Darling-White M, Huber JE. The impact of expiratory muscle strength training on speech breathing in individuals with Parkinson's disease: a preliminary study. Am. J. Speech Lang. Pathol. 26(4), 1159–1166 (2017).
  MedlineGoogle Scholar
• 45 Whitfield JA, Goberman AM. Articulatory–acoustic vowel space: application to clear speech in individuals with Parkinson's disease. J. Commun. Disord. 51, 19–28 (2014).
  MedlineGoogle Scholar
• 46 Lombard LE, Steinhauer KM. A novel treatment for hypophonic voice: twang therapy. J. Voice 21(3), 294–299 (2007).
  MedlineGoogle Scholar
• 47 Perju-Dumbrava L, Lau K, Phyland D et al. Arytenoid cartilage movements are hypokinetic in Parkinson's disease: a quantitative dynamic computerised tomographic study. PLoS ONE 12(11), e0186611 (2017).
  MedlineGoogle Scholar
• 48 Hamdan A-L, Khalifee E, Tabet G. Unilateral vocal fold paralysis in Parkinson disease: case report and review of the literature. J. Voice doi:10.1016/j.jvoice.2017.09.007 (2017) (Epub ahead of print).
  Google Scholar
• 49 Pompili A, Abad A, Romano P et al. Automatic detection of Parkinson's disease: an experimental analysis of common speech production tasks used for diagnosis. Presented at: International Conference on Text, Speech, and Dialogue. Prague, Czech Republic, August 27 2017.
  Google Scholar
• 50 Jeancolas L, Benali H, Benkelfat B-E et al. Automatic detection of early stages of Parkinson's disease through acoustic voice analysis with mel-frequency cepstral coefficients. Presented at: Advanced Technologies for Signal and Image Processing (ATSIP), 2017 International Conference. Fez, Morocco, 22 May 2017.
  Google Scholar
• 51 Ramig LO, Fox C, Sapir S. Speech treatment for Parkinson's disease. Expert Rev. Neurother. 8(2), 297–309 (2008).
  MedlineGoogle Scholar
• 52 Hlavnička J, Čmejla R, Tykalová T, Šonka K, Růžička E, Rusz J. Automated analysis of connected speech reveals early biomarkers of Parkinson's disease in patients with rapid eye movement sleep behaviour disorder. Sci. Rep. 7(1), 12 (2017).
  MedlineGoogle Scholar
• 53 Rusz J, Bonnet C, Klempíř J et al. Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. J. Neurol. 262(4), 992–1001 (2015).
  Medline CASGoogle Scholar
• 54 Whitfield JA, Goberman AM. Speech motor sequence learning: acquisition and retention in Parkinson disease and normal aging. J. Speech Lang. Hear. Res. 60(6), 1477–1492 (2017).
  MedlineGoogle Scholar
• 55 Ziegler W, Ackermann H. Subcortical contributions to motor speech: phylogenetic, developmental, clinical. Trends Neurosci. 40(8), 458–468 (2017).
  Medline CASGoogle Scholar
• 56 Rusz J, Tykalová T, Krupička R et al. Comparative analysis of speech impairment and upper limb motor dysfunction in Parkinson's disease. J. Neural. Transm. 124(4), 463–470 (2017).
  MedlineGoogle Scholar
• 57 Moreau C, Ozsancak C, Blatt JL, Derambure P, Destee A, Defebvre L. Oral festination in Parkinson's disease: biomechanical analysis and correlation with festination and freezing of gait. Mov. Disord. 22(10), 1503–1506 (2007).
  MedlineGoogle Scholar
• 58 Cantiniaux S, Vaugoyeau M, Robert D et al. Comparative analysis of gait and speech in Parkinson's disease: hypokinetic or dysrhythmic disorders? J. Neurol. Neurosurg. Psych. 81(2), 177–184 (2010).
  MedlineGoogle Scholar
• 59 Park HK, Yoo JY, Kwon M et al. Gait freezing and speech disturbance in Parkinson's disease. Neurol. Sci. 35(3), 357–363 (2014).
  Medline CASGoogle Scholar
• 60 Rektorova I, Mekyska J, Janousova E et al. Speech prosody impairment predicts cognitive decline in Parkinson's disease. Parkinsonism Relat. Disord. 29, 90–95 (2016).
  MedlineGoogle Scholar
• 61 Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Auzou P. Treatments for dysarthria in Parkinson's disease. Lancet Neurol. 3(9), 547–556 (2004).
  MedlineGoogle Scholar
• 62 Sapir S. Multiple factors are involved in the dysarthria associated with Parkinson's disease: a review with implications for clinical practice and research. J. Speech Lang. Hear. Res. 57(4), 1330–1343 (2014).
  MedlineGoogle Scholar
• 63 Hanson DG, Gerratt BR, Ward PH. Cinegraphic observations of laryngeal function in Parkinson's disease. Laryngoscope 94(3), 348–353 (1984).
  Medline CASGoogle Scholar
• 64 Leopold NA, Kagel MC. Laryngeal deglutition movement in Parkinson's disease. Neurology 48(2), 373–375 (1997).
  Medline CASGoogle Scholar
• 65 Friedman JH. Misperceptions and Parkinson's disease. J. Neurol. Sci. 374, 42–46 (2017).
  MedlineGoogle Scholar
• 66 Brajot F-X, Shiller DM, Gracco VL. Autophonic loudness perception in Parkinson's disease. J. Acoust. Soc. Am. 139(3), 1364–1371 (2016).
  MedlineGoogle Scholar
• 67 Huang X, Chen X, Yan N et al. The impact of Parkinson's disease on the cortical mechanisms that support auditory–motor integration for voice control. Hum. Brain Mapp. 37(12), 4248–4261 (2016).
  MedlineGoogle Scholar
• 68 Ho AK, Bradshaw JL, Iansek R. Volume perception in parkinsonian speech. Mov. Disord. 15(6), 1125–1131 (2000).
  Medline CASGoogle Scholar
• 69 Ho AK, Iansek R, Bradshaw JL. Regulation of parkinsonian speech volume: the effect of interlocuter distance. J. Neurol. Neurosurg. Psych. 67(2), 199–202 (1999).
  Medline CASGoogle Scholar
• 70 Arnold C, Gehrig J, Gispert S, Seifried C, Kell CA. Pathomechanisms and compensatory efforts related to Parkinsonian speech. Neuroimage Clin. 4, 82–97 (2014).
  MedlineGoogle Scholar
• 71 Schneider JS, Diamond SG, Markham CH. Deficits in orofacial sensorimotor function in Parkinson's disease. Ann. Neurol. 19(3), 275–282 (1986).
  Medline CASGoogle Scholar
• 72 Schalling E, Johansson K, Hartelius L. Speech and communication changes reported by people with Parkinson's disease. Folia Phoniatr. Logop. 69(3), 131–141 (2017).
  MedlineGoogle Scholar
• 73 Berke GS, Gerratt B, Kreiman J, Jackson K. Treatment of Parkinson hypophonia with percutaneous collagen augmentation. Laryngoscope 109(8), 1295–1299 (1999).
  Medline CASGoogle Scholar
• 74 Krischke S, Weigelt S, Hoppe U et al. Quality of life in dysphonic patients. J. Voice 19(1), 132–137 (2005).
  MedlineGoogle Scholar
• 75 Sunwoo MK, Hong JY, Lee JE, Lee HS, Lee PH, Sohn YH. Depression and voice handicap in Parkinson disease. J. Neurol. Sci. 346(1–2), 112–115 (2014).
  MedlineGoogle Scholar
• 76 Miller N, Noble E, Jones D, Burn D. Life with communication changes in Parkinson's disease. Age Ageing 35(3), 235–239 (2006).
  MedlineGoogle Scholar
• 77 Liotti M, Ramig L, Vogel D et al. Hypophonia in Parkinson's disease neural correlates of voice treatment revealed by PET. Neurology 60(3), 432–440 (2003).
  Medline CASGoogle Scholar
• 78 Yorkston K, Baylor C, Britton D. Speech versus speaking: the experiences of people with Parkinson's disease and implications for intervention. Am. J. Speech Lang. Pathol. 26(2S), 561–568 (2017).
  MedlineGoogle Scholar
• 79 Logemann JA, Fisher HB, Boshes B, Blonsky ER. Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J. Speech Hear. Disord. 43(1), 47–57 (1978).
  Medline CASGoogle Scholar
• 80 Seppi K, Weintraub D, Coelho M et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26(S3), S42–S80 (2011).
  MedlineGoogle Scholar
• 81 Fox SH, Katzenschlager R, Lim SY et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26(S3), S2–S41 (2011).
  MedlineGoogle Scholar
• 82 Rusz J, Tykalová T, Klempíř J, Čmejla R, Růžička E. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients. J. Neural. Transm. 123(4), 379–387 (2016).
  Medline CASGoogle Scholar
• 83 LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease a look backward and forward. Neurology 86(14 Suppl. 1), S3–S12 (2016).
  Medline CASGoogle Scholar
• 84 Thanvi B, Lo T. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad. Med. J. 80(946), 452–458 (2004).
  Medline CASGoogle Scholar
• 85 Rigrodsky S, Morrison E. Speech changes in parkinsonism during L-dopa therapy: preliminary findings. J. Am. Geriatr. Soc. 18(2), 142–151 (1970).
  Medline CASGoogle Scholar
• 86 Wolfe VI, Garvin JS, Bacon M, Waldrop W. Speech changes in Parkinson's disease during treatment with L-dopa. J. Commun. Disord. 8(3), 271–279 (1975).
  Medline CASGoogle Scholar
• 87 Biary N, Pimental PA, Langenberg PW. A double-blind trial of clonazepam in the treatment of parkinsonian dysarthria. Neurology 38(2), 255–255 (1988).
  Medline CASGoogle Scholar
• 88 Okada Y, Murata M, Toda T. Effects of levodopa on vowel articulation in patients with Parkinson's disease. Kobe J. Med. Sci. 61(5), E144–E154 (2016).
  MedlineGoogle Scholar
• 89 Fabbri M, Guimarães I, Cardoso R et al. Speech and voice response to a levodopa challenge in late-stage Parkinson's disease. Front. Neurol. 8, 432 (2017).
  MedlineGoogle Scholar
• 90 Tykalová T, Rusz J, Čmejla R et al. Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study. J. Neural. Transm. 122(8), 1135–1142 (2015).
  MedlineGoogle Scholar
• 91 Civier O, Bullock D, Max L, Guenther FH. Computational modeling of stuttering caused by impairments in a basal ganglia thalamo-cortical circuit involved in syllable selection and initiation. Brain Lang. 126(3), 263–278 (2013).
  MedlineGoogle Scholar
• 92 Jeankovic J, Marsden CD. Therapeutic Strategies in Parkinson's Disease. Williams & Wilkins, MD, USA (1997).
  Google Scholar
• 93 Dezsi L, Vécsei L. Monoamine oxidase B inhibitors in Parkinson's disease. CNS Neurol. Disord. Drug Targets 16(4), 425–439 (2017).
  Medline CASGoogle Scholar
• 94 Hauser RA, Li R, Pérez A et al. Longer duration of MAO-B inhibitor exposure is associated with less clinical decline in Parkinson's disease: an analysis of NET-PD LS1. J. Parkinsons Dis. 7(1), 117–127 (2017).
  Medline CASGoogle Scholar
• 95 Shea BR, Drummond SS, Metzer WS, Krueger KM. Effect of selegiline on speech performance in Parkinson's disease. Folia Phoniatr. 45(1), 40–46 (1993).
  Medline CASGoogle Scholar
• 96 Stewart C, Winfield L, Hunt A et al. Speech dysfunction in early Parkinson's disease. Mov. Disord. 10(5), 562–565 (1995).
  Medline CASGoogle Scholar
• 97 Sackley CM, Smith CH, Rick C et al. Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial. Trials 15(1), 213 (2014).
  MedlineGoogle Scholar
• 98 Miller N, Noble E, Jones D, Deane KH, Gibb C. Survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: patients’ and carers’ perspectives. Int. J. Lang. Commun. Disord. 1–10 (2015).
  MedlineGoogle Scholar
• 99 Sackley CM, Smith CH, Rick CE et al. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot). Pilot Feasibility Stud. 4(1), 30 (2018).
  MedlineGoogle Scholar
• 100 Scott S, Caird F. Speech therapy for Parkinson's disease. J. Neurol. Neurosurg. Psych. 46(2), 140–144 (1983).
  Medline CASGoogle Scholar
• 101 Tasker RR, Siqueira J, Hawrylyshyn P, Organ LW. What happened to VIM thalamotomy for Parkinson's disease? Appl. Neurophysiol. 46(1–4), 68–83 (1983).
  Medline CASGoogle Scholar
• 102 Ahmad N, Ahmad M, Asif M, Shafiq K. Thalamotomy for Parkinson's disease. Ann. King Edward Med. Uni. 6(4), 364–366 (2018).
  Google Scholar
• 103 Quaglieri CE, Celesia GG. Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients. Eur. Neurol. 15(1), 34–39 (1977).
  Medline CASGoogle Scholar
• 104 Alomar S, King NK, Tam J, Bari AA, Hamani C, Lozano AM. Speech and language adverse effects after thalamotomy and deep brain stimulation in patients with movement disorders: a meta-analysis. Mov. Disord. 32(1), 53–63 (2017).
  MedlineGoogle Scholar
• 105 Jenkins A. Speech defects following stereotaxic operations for the relief of tremor and rigidity in parkinsonism. Med. J. Aust. 1(14), 585 (1968).
  Medline CASGoogle Scholar
• 106 Schulz GM, Peterson T, Sapienza CM, Greer M, Friedman W. Voice and speech characteristics of persons with Parkinson's disease pre-and post-pallidotomy surgery: preliminary findings. J. Speech Lang. Hear. Res. 42(5), 1176–1194 (1999).
  Medline CASGoogle Scholar
• 107 Kinfe TM. Stereotactic MR-guided focused ultrasound deep brain lesioning: the resurrection of posteroventral pallidotomy and thalamotomy for Parkinson's disease? Acta Neurochir. 159(7), 1367–1369 (2017).
  MedlineGoogle Scholar
• 108 Rossi M, Cerquetti D, Mandolesi J, Merello M. Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease. Parkinsons Dis. Curr. Future Ther. Clin. Trials 175–185 (2016).
  Google Scholar
• 109 Schulz GM, Greer M, Friedman W. Changes in vocal intensity in Parkinson's disease following pallidotomy surgery. J. Voice 14(4), 589–606 (2000).
  Medline CASGoogle Scholar
• 110 Olanow CW, Brin MF, Obeso J. The role of deep brain stimulation as a surgical treatment for Parkinson's disease. Neurology 55(12 Suppl. 6), S60–S66 (2000).
  Medline CASGoogle Scholar
• 111 Skodda S. Effect of deep brain stimulation on speech performance in Parkinson's disease. Parkinsons Dis. 2012, 1–10 (2012).
  Google Scholar
• 112 Skodda S, Grönheit W, Schlegel U, Südmeyer M, Schnitzler A, Wojtecki L. Effect of subthalamic stimulation on voice and speech in Parkinson's disease: for the better or worse? Front. Neurol. 4, 218 (2014).
  MedlineGoogle Scholar
• 113 Moro E. Parkinson disease: let's listen to patients with PD after deep brain stimulation. Nat. Rev. Neurol. 10(10), 550 (2014).
  MedlineGoogle Scholar
• 114 Aldridge D, Theodoros D, Angwin A, Vogel AP. Speech outcomes in Parkinson's disease after subthalamic nucleus deep brain stimulation: A systematic review. Parkinsonism Relat. Disord. 33, 3–11 (2016).
  MedlineGoogle Scholar
• 115 Hariz M. My 25 stimulating years with DBS in Parkinson's disease. J. Parkinsons Dis. 7(s1), S33–S41 (2017).
  MedlineGoogle Scholar
• 116 Gross C, Rougier A, Guehl D, Boraud T, Julien J, Bioulac B. High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. J. Neurosurg. 87(4), 491–498 (1997).
  Medline CASGoogle Scholar
• 117 Arocho-Quinones EV, Hammer MJ, Bock JM, Pahapill PA. Effects of deep brain stimulation on vocal fold immobility in Parkinson's disease. Surg. Neurol. Int. (2017). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339919/.
  MedlineGoogle Scholar
• 118 Tsuboi T, Watanabe H, Tanaka Y et al. Distinct phenotypes of speech and voice disorders in Parkinson's disease after subthalamic nucleus deep brain stimulation. J. Neurol. Neurosurg. Psych. 86(8), 856–864 (2015).
  MedlineGoogle Scholar
• 119 Fournet M, Chiuvé SC, Momjian S, Burkhard P, Laganaro M. Modulation of voice and speech parameters after subthalamic nucleus deep brain stimulation in Parkinson's disease. Brain Stimul. 10(2), 470 (2017).
  Google Scholar
• 120 Sewall GK, Jiang J, Ford CN. Clinical evaluation of Parkinson's-related dysphonia. Laryngoscope 116(10), 1740–1744 (2006).
  MedlineGoogle Scholar
• 121 Mu L, Sobotka S, Chen J et al. Altered pharyngeal muscles in Parkinson disease. J. Neuropath. Exp. Neurol. 71(6), 520–530 (2012).
  MedlineGoogle Scholar
• 122 Volk GF, Guntinas-Lichius O. Vocal Cord Immobility: Central Origin. In: Sittel C, Guntinas-Lichius O (Eds). Neurolaryngology. Springer, NY, USA, 73–80 (2018).
  Google Scholar
• 123 Gibbins N, Awad R, Harris S, Aymat A. The diagnosis, clinical findings and treatment options for Parkinson's disease patients attending a tertiary referral voice clinic. J. Laryngol. Otol. 131(4), 357–362 (2017).
  Medline CASGoogle Scholar
• 124 Orellana M, Badía P, Napolitano C. Injection laryngoplasty treatment for vocal atrophy in the elderly. MOJ Gerontol. Ger. 2(2), 00043 (2017).
  Google Scholar
• 125 Blackshaw H, Carding P, Jepson M et al. Does laryngeal reinnervation or type I thyroplasty give better voice results for patients with unilateral vocal fold paralysis (VOCALIST): study protocol for a feasibility randomised controlled trial. BMJ Open 7(9), e016871 (2017).
  MedlineGoogle Scholar
• 126 Allensworth JJ, O'Dell K, Ziegler A, Bryans L, Flint P, Schindler J. Treatment outcomes of bilateral medialization thyroplasty for presbylaryngis. J. Voice doi:10.1016/j.jvoice.2017.10 (2018) (Epub ahead of print).
  MedlineGoogle Scholar
• 127 Kaneko M, Hirano S, Tateya I et al. Multidimensional analysis on the effect of vocal function exercises on aged vocal fold atrophy. J. Voice 29(5), 638–644 (2015).
  MedlineGoogle Scholar
• 128 Belafsky PC, Postma GN. Vocal fold augmentation with calcium hydroxylapatite. Otolaryngol. Head Neck Surg. 131(4), 351–354 (2004).
  MedlineGoogle Scholar
• 129 Mallur PS, Morrison MP, Postma GN, Amin MR, Rosen CA. Safety and efficacy of carboxymethylcellulose in the treatment of glottic insufficiency. Laryngoscope 122(2), 322–326 (2012).
  Medline CASGoogle Scholar
• 130 Marmur ES, Phelps R, Goldberg DJ. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J. Cosmet. Laser Ther. 6(4), 223–226 (2004).
  MedlineGoogle Scholar
• 131 Hertegård S, Hallén L, Laurent C et al. Cross-linked hyaluronan used as augmentation substance for treatment of glottal insufficiency: safety aspects and vocal fold function. Laryngoscope 112(12), 2211–2219 (2002).
  MedlineGoogle Scholar
• 132 Wen M-H, Cheng P-W, Liao L-J, Chou H-W, Wang C-T. Treatment outcomes of injection laryngoplasty using cross-linked porcine collagen and hyaluronic acid. Otolaryngol. Head Neck Surg. 149(6), 900–906 (2013).
  MedlineGoogle Scholar
• 133 Remacle M, Lawson G. Results with collagen injection into the vocal folds for medialization. Curr. Opin. Otolaryngol. Head Neck Surg. 15(3), 148–152 (2007).
  MedlineGoogle Scholar
• 134 Rosen CA, Gartner-Schmidt J, Casiano R et al. Vocal fold augmentation with calcium hydroxylapatite: twelve-month report. Laryngoscope 119(5), 1033–1041 (2009).
  Medline CASGoogle Scholar
• 135 Cohen JC, Reisacher W, Malone M, Sulica L. Severe systemic reaction from calcium hydroxylapatite vocal fold filler. Laryngoscope 123(9), 2237–2239 (2013).
  Medline CASGoogle Scholar
• 136 McCulloch TM, Andrews BT, Hoffman HT, Graham SM, Karnell MP, Minnick C. Long-term follow-up of fat injection laryngoplasty for unilateral vocal cord paralysis. Laryngoscope 112(7), 1235–1238 (2002).
  MedlineGoogle Scholar
• 137 Havas TE, Priestley KJ. Autologous fat injection laryngoplasty for unilateral vocal fold paralysis. ANZ J. Surg. 73(11), 938–943 (2003).
  MedlineGoogle Scholar
• 138 Nanjundeswaran CD, Carroll TL. Meta-analysis for medical intervention of unilateral vocal fold paralysis: limited evidence on generalization of voice outcomes. Evid. Based Commun. Assess. Interv. 11(1–2), 42–46 (2017).
  Google Scholar
• 139 Mallur PS, Rosen CA. Vocal fold injection: review of indications, techniques, and materials for augmentation. Clin. Exp. Otorhinolaryngol. 3(4), 177 (2010).
  MedlineGoogle Scholar
• 140 Rontal E, Rontal M. Vocal cord injection techniques. Otolaryngologic Clin. N. Am. 24(5), 1141–1149 (1991).
  Medline CASGoogle Scholar
• 141 Cha W, Ro JH, Wang SG et al. Development of a device for real-time light-guided vocal fold injection: a preliminary report. Laryngoscope 126(4), 936–940 (2016).
  MedlineGoogle Scholar
• 142 Crawley BK, Dehom S, Kutzner E, Murry T, Krishna P, Hata J. Perception and duration of pain after office-based vocal fold injection augmentation. Laryngoscope 128(4), 929–934 (2018).
  MedlineGoogle Scholar
• 143 Kwon T-K, Buckmire R. Injection laryngoplasty for management of unilateral vocal fold paralysis. Curr. Opin. Otolaryngol. Head Neck Surg. 12(6), 538–542 (2004).
  MedlineGoogle Scholar
• 144 Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov. Disord. 18(10), 1190–1192 (2003).
  MedlineGoogle Scholar
• 145 Kim SH, Kearney JJ, Atkins JP. Percutaneous laryngeal collagen augmentation for treatment of parkinsonian hypophonia. Otolaryngol. Head Neck Surg. 126(6), 653–656 (2002).
  MedlineGoogle Scholar
• 146 Ramig LO, Dromey C. Aerodynamic mechanisms underlying treatment-related changes in vocal intensity in patients with Parkinson disease. J. Speech Lang. Hear. Res. 39(4), 798–807 (1996).
  CASGoogle Scholar